Insulet Corporation has launched its innovative Omnipod 5 and Omnipod Discover offerings in the Middle East. With this launch, the company aims to transform diabetes care and improve outcomes for patients living with this lifelong condition. This week, Insulet unveiled the rollout at the 16th Emirates Diabetes and Endocrine Congress in Dubai. Consequently, the event marks a major milestone for diabetes technology access in Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates.
The commercial launch of Omnipod 5 and Omnipod Discover offers significant benefits for people managing type 1 diabetes in the region. Here, the daily burden of blood glucose management remains high. Omnipod 5 now works with leading continuous glucose monitoring sensors. Meanwhile, Omnipod Discover provides advanced data analytics. Together, these tools help users and care teams manage diabetes more efficiently.
Unlike traditional pumps, the Omnipod 5 Automated Insulin Delivery (AID) System is tubeless and wearable. It adjusts insulin delivery every five minutes based on sensor readings. By eliminating the need for multiple daily injections, the system continuously adapts dosing. Clinical evaluations show that it improves glycemic outcomes. As a result, patients experience better “time in range” and lower HbA1c levels.
Insulet also introduced Omnipod Discover, a data platform that turns complex glucose and insulin information into actionable insights. Caregivers and healthcare providers can use the platform to identify patterns quickly. In addition, they can make faster clinical decisions and provide personalized patient care.
“Bringing Omnipod 5 and Omnipod Discover to a region with significant unmet need is a major step forward,” said Pat Crannell, Insulet Senior Vice President and International General Manager. Furthermore, Crannell added that the coordinated launch builds on Insulet’s global momentum. Therefore, the goal is to improve daily life for people with diabetes.
Omnipod 5 uses SmartAdjust technology to fine-tune insulin delivery continuously. The system is waterproof, discreet, and designed for everyday use. Additionally, it supports daily activities with minimal interruption. Children and adults aged two years and older with type 1 diabetes can now access Omnipod 5 in the newly launched markets.
Healthcare professionals have welcomed the rollout. They also highlighted its potential to improve the quality of life and reduce the mental burden of self-management. Dr. Mohammed Almehthel, Medical Director and Diabetes Technology Section Head at King Fahad Medical City in Saudi Arabia, emphasized that regional care standards increasingly adopt advanced technologies like Omnipod 5. Consequently, these tools help enhance outcomes in daily living.
Local families are responding positively as well. Khalid Al Shethri, a father from Riyadh, expressed excitement about his nine-year-old daughter Yasmeen’s access to Omnipod 5. Moreover, he noted that the system gives her a sense of freedom and confidence. Daily glucose monitoring had previously limited her independence.
Regional health systems also stand to benefit from Omnipod Discover. By consolidating glucose and insulin data into intuitive trends, providers can optimize treatment plans. In addition, they can respond proactively to patient needs. This platform reduces workflow pressures on care teams while supporting more targeted patient education and follow-up.
Insulet’s Middle East expansion aligns with its broader global strategy. Omnipod 5 is now available in 19 countries, including recent launches in Europe and Australia. Furthermore, the company plans to introduce it in Spain, Greece, and Croatia in late 2026 and early 2027. As a result, access will expand to more people managing diabetes worldwide.
Industry analysts note that combining user-friendly data platforms like Omnipod Discover with automated insulin delivery systems such as Omnipod 5 helps shift diabetes care toward a proactive, predictive model. Consequently, this approach improves engagement between patients and providers. It is particularly beneficial in regions with high diabetes prevalence and limited access to advanced technology.
By launching Omnipod 5 and Omnipod Discover, Insulet aims to reduce the daily burden of diabetes management. Therefore, patients can focus more on life’s opportunities rather than constant glucose calculations. Although adoption varies across markets, this rollout represents a meaningful step in expanding access to sophisticated diabetes care tools. Moreover, these solutions improve both health outcomes and quality of life.
